Petrovic Fabijan, Aleksandra http://orcid.org/0000-0003-3172-2375
Lin, Ruby C. Y. http://orcid.org/0000-0003-4163-511X
Ho, Josephine
Maddocks, Susan
Ben Zakour, Nouri L.
Iredell, Jonathan R. http://orcid.org/0000-0003-2469-7060
Khalid, Ali
Venturini, Carola
Chard, Richard
Morales, Sandra
Sandaradura, Indy
Gilbey, Tim
,
Funding for this research was provided by:
Partially from Ampliphi Biosciences - AmpliPhi 2018
Department of Health | National Health and Medical Research Council (1107322, 1104232, 1104232, 1107322, 1104232, 1107322)
Article History
Received: 7 May 2019
Accepted: 5 November 2019
First Online: 17 February 2020
Change Date: 5 March 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41564-020-0698-9
Competing interests
: No personal financial interest was received by the listed authors or WBTT. A provisional patent has been filed in the United States, dated 4 October 2018. R.C.Y.L., J.R.I., A.P.F. and S. Morales are the inventors (attorney docket no. 054249-512; ‘Bacteriophage treatment and reduction of inflammatory response’). ABPH is the sole proprietary owner of AB-SA01. J.R.I. has previously acted as a clinical advisor to C3J Therapeutics. C3J Therapeutics and ABPH announced a merger on 4 January 2019 to become Armata Pharmaceuticals.